Pzena Investment Management LLC Trims Holdings in USANA Health Sciences, Inc. $USNA

Pzena Investment Management LLC reduced its stake in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 2.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,108,933 shares of the company’s stock after selling 25,496 shares during the period. Pzena Investment Management LLC owned about 0.06% of USANA Health Sciences worth $19,373,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of USNA. Inspire Investing LLC raised its stake in shares of USANA Health Sciences by 22.6% in the 1st quarter. Inspire Investing LLC now owns 29,362 shares of the company’s stock valued at $513,000 after purchasing an additional 5,419 shares in the last quarter. Hsbc Holdings PLC grew its stake in USANA Health Sciences by 72.8% in the fourth quarter. Hsbc Holdings PLC now owns 13,334 shares of the company’s stock worth $259,000 after purchasing an additional 5,617 shares in the last quarter. State of Tennessee Department of Treasury grew its stake in USANA Health Sciences by 307.8% in the fourth quarter. State of Tennessee Department of Treasury now owns 29,290 shares of the company’s stock worth $636,000 after purchasing an additional 22,108 shares in the last quarter. Empowered Funds LLC increased its holdings in USANA Health Sciences by 10.6% in the fourth quarter. Empowered Funds LLC now owns 60,437 shares of the company’s stock valued at $1,186,000 after buying an additional 5,782 shares during the last quarter. Finally, Tudor Investment Corp ET AL increased its holdings in USANA Health Sciences by 354.8% in the fourth quarter. Tudor Investment Corp ET AL now owns 109,686 shares of the company’s stock valued at $2,153,000 after buying an additional 85,570 shares during the last quarter. Institutional investors own 54.25% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on USNA shares. Wall Street Zen upgraded USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Saturday, June 20th. Zacks Research cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 22nd. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a report on Wednesday, June 24th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.

USANA Health Sciences Stock Performance

USNA stock opened at $21.49 on Friday. USANA Health Sciences, Inc. has a 1 year low of $16.60 and a 1 year high of $38.32. The stock has a market capitalization of $396.79 million, a price-to-earnings ratio of 45.73, a PEG ratio of 0.85 and a beta of 0.73. The stock’s fifty day moving average is $19.04 and its two-hundred day moving average is $19.43.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.44 by $0.17. The business had revenue of $250.22 million during the quarter, compared to analyst estimates of $240.99 million. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. As a group, analysts predict that USANA Health Sciences, Inc. will post 2.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director John Turman Fleming sold 2,450 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $17.93, for a total transaction of $43,928.50. Following the transaction, the director directly owned 4,230 shares of the company’s stock, valued at approximately $75,843.90. This trade represents a 36.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brent Neidig sold 5,002 shares of USANA Health Sciences stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $19.45, for a total transaction of $97,288.90. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 17,660 shares of company stock valued at $336,579 in the last quarter. 0.82% of the stock is owned by insiders.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.